Skip to main content
NIH funding notice PAR-18-226

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)

Closed on October 19, 2018.

Posted
November 30, 2017
Close date
October 19, 2018
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $937,500 in first-year total cost, median $468,750.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 IXN-O (04)]2

Most frequent institutions

  1. UNIVERSITY OF MARYLAND BALTIMORE1
  2. VANDERBILT UNIVERSITY1
Competing awards under PAR-18-226 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2019Making and breaking opioid memories to prevent relapse1DP1DA048931-01CALIPARI, ERINVANDERBILT UNIVERSITY, TN$474,000ZDA1
2019A Multivariate Mediation and Deep Learning Framework for Genome-Connectome -Substance Use Research1DP1DA048968-01CHEN, SHUOUNIVERSITY OF MARYLAND BALTIMORE, MD$463,500ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.